Who is sponsoring NCT03899571?

NCT03899571 is sponsored by University Medical Centre Ljubljana.

What drugs are being tested in NCT03899571?

Interventions in NCT03899571: Oseltamivir Oral Capsule for 5 days post-exposure, Oseltamivir Oral Capsule for 10 days post-exposure.

What condition does NCT03899571 study?

NCT03899571 studies Influenza, Human.

Is NCT03899571 still recruiting?

NCT03899571 is currently completed. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT03899571

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prophylactic Treatment With Oseltamivir

Completed NA Last updated 3 November 2020

What this trial tests

NA trial testing Oseltamivir Oral Capsule for 5 days post-exposure in Influenza, Human in 222 participants. Completed in 31 March 2020.

Timeline

22 January 2019

Primary endpoint
31 March 2020

31 March 2020

Quick facts

Lead sponsor	University Medical Centre Ljubljana
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	222
Start date	22 January 2019
Primary completion	31 March 2020
Estimated completion	31 March 2020
Sites	1 location across Slovenia

Drugs / interventions tested

Oseltamivir Oral Capsule for 5 days post-exposure — full drug profile →
Oseltamivir Oral Capsule for 10 days post-exposure — full drug profile →

Conditions studied

Influenza, Human — all drugs for Influenza, Human →

Sponsor

University Medical Centre Ljubljana

Who can join

18 and older, any sex, with Influenza, Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study.
Lepen L, Blagus R, Velušček M, Saletinger R, et al · · 2020 · cited 4× · PMID 32766383 · DOI 10.1093/ofid/ofaa240

Verify or expand the search:

Other recruiting trials for Influenza, Human

Currently open trials in the same condition.

NCT07204964 — A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above · Phase 2 · active not recruiting
NCT07121192 — A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older · Phase 2 · active not recruiting
NCT05921448 — Vaccine Pandemic Preparedness Through Airway Immunology Characterization · EARLY_PHASE1 · active not recruiting
NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
NCT06622590 — Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine · Phase 1 · active not recruiting

Other University Medical Centre Ljubljana trials

Trials by the same sponsor.

NCT07466472 — Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity · not yet recruiting
NCT07446244 — Catheter Ablation of Advanced Forms of Atrial Fibrillation · NA · enrolling by invitation
NCT07109076 — Effect of Immediate Skin-to-Skin Contact on Neonatal Heart Rate Variability After Cesarean Secton · NA · recruiting
NCT07354880 — Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease · Phase 4 · not yet recruiting
NCT07496736 — Post-exposure Influenza Prophylaxis in a Hospital Setting · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03899571 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Centre Ljubljana
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899571.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing